| 1 | Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis显示文摘AIM: To investigate the effects of troglitazone (TGZ), an anti-diabetic drug which activates peroxisome proliferatoractivated receptor-γ (PPAR-γ), for liver tissue repair, and the development of ductular reaction, following common bile duct ligation (BDL) in rats.METHODS: Rats were supplemented with TGZ (0.2% w/w in the pelleted food) for 1 wk before BDL or sham operation.Animals were killed at 1, 2, or 4 wk after surgery.RESULTS: The development of liver fibrosis was reduced in rats receiving TGZ, as indicated by significant decreases of procollagen type Ⅰ gene expression and liver hydroxyproline levels. Accumulation of α-smooth-muscle actin (SMA)-expressing cells surrounding newly formed bile ducts following BDL, as well as total hepatic levels of SMA were partially inhibited by TGZ treatment, indicating the presence of a reduced number and/or activation of hepatic stellate cells (HSC) and myofibroblasts. Development of the ductular reaction was inhibited by TGZ, as indicated by histochemical evaluation and hepatic activity of γ-glutamyltransferase (GGT).CONCLUSION: Treatment with thiazolidinedione reduces ductular proliferation and fibrosis in a model of chronic cholestasis, and suggests that limiting cholangiocyte proliferation may contribute to the lower development of scarring in this system. | Fabio Marra Raffaella DeFranco Gaia Robino Erica Novo Eva Efsen Sabrina Pastacaldi Elena Zamara Alessandro Vercelli Benedetta Lottini Carlo Spirli Mario Strazzabosco Massimo Pinzani Maurizio Parola | 2005 | World Journal of Gastroenterology2005，11，32： | 9 |
您所在的机构暂未开通此部分的功能，请联系管理员